Agreement to increase the flow of ideas from laboratory to clinic

July 11, 2006

The University of Manchester and pharmaceutical company AstraZeneca have signed an agreement to enhance each organisation's research into diseases such as cancer, inflammatory diseases and diabetes and obesity.

The agreement sets out how the University and AstraZeneca will work together to identify new ways to treat disease and to nurture and enhance discovery, pre-clinical and clinical research in a bid to better understand a variety of conditions. Under the agreement the University and AstraZeneca will exchange staff, share facilities and encourage joint ventures through long-term funded collaborations.

The parties will also focus on enabling technologies such as imaging, informatics and chemistry that have the potential to identify and accelerate drug discovery in a number of different disease areas.

The agreement formalises previous close contacts between the parties such as the appointment of Professor Hans Westerhoff as AstraZeneca Professor of Systems Biology and the development of collaborative science networks.

A key component of the agreement is the shared benefits that will accrue to the parties, including: the faster translation of high-impact science to the clinic and joint efforts to secure the UK science base.

An early example of the collaborative approach has been the establishment of a joint cancer alliance steering group focusing on translational science in the areas of cancer imaging, serological biomarkers of cancer and Phase I cancer clinical trials between AstraZeneca and the Manchester Cancer Research Centre. Early successes from this group include the establishment of a biomarkers network to share expertise between the two parties, a £1.25m project over three years focusing on serological markers of cancer; and pre-clinical and clinical fellowships in cancer imaging.

Professor Alan North, University of Manchester Vice-President and Dean of the Faculty of Life Sciences, said: "Teaming up with a company like AstraZeneca will increase our ability to attract the very best researchers, while providing AstraZeneca with access to new technologies, disease models and a large patient research base. The focus that working with AstraZeneca has brought has already helped us to understand how more than 40 individual academics in diverse areas across the University could be grouped together to provide insights into inflammatory diseases such as asthma and arthritis research."

Dr Les Hughes, Global Vice-President, Cancer and Infection, at AstraZeneca, said: "The University of Manchester is the UK's largest traditional university and has an impressive track record of research in the fields of Physical and Biomedical Science. This alliance will pool areas of expertise within our respective organisations to further our shared goals of delivering safe and effective medicines to the patients who need them."

The University of Manchester was formed on October 1st 2004 by the fusion of the University of Manchester Institute of Science and Technology (UMIST) and the Victoria University of Manchester (VUM). The resulting institution is one of Europe's leading higher-education institutions with an unrivalled quality, breadth and volume of research activity. Historically, no fewer than 23 former staff and students have gone on to become Nobel Prize winners. There are more than 50 specialist research centres and groups at the University, each undertaking pioneering research into areas ranging from cancer and arthritis to bioinformatics and imaging analysis.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $23.95 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
-end-
Notes to editors:

For further details about AstraZeneca visit
www.astrazeneca.com

For further details about The University of Manchester visit
www.manchester.ac.uk

University of Manchester

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.